UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
University of Arkansas
Study ID
NCT02140840
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trametinib — DRUG
    2 mg of Trametinib daily by mouth in 28 day cycles

Study Details

The purpose of this study is to evaluate the overall response rate of Trametinib when administered orally to patients with relapsed or refractory multiple myeloma

Key Dates

Start date
Mar 31, 2015
Status verified
Apr 2016
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

The response rate of Trametinib when administered orally to patients with relapsed multiple myeloma [ Time Frame: 28 day ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Arkansas for Medical SciencesLittle RockArkansas72205-

Find similar trials in Little Rock, AR

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
University of Arkansas for Medical Sciences· Little Rock, AR

Related Studies